Evidence map›Paper›PMID 33184347›Full record

ArticleScientific reports2020

Withaferin A activates TRIM16 for its anti-cancer activity in melanoma.

Zsuzsanna Nagy, Belamy B Cheung, Wing Tsang, Owen Tan, Mika Herath, Olivia C Ciampa, Fatima Shadma, Daniel R Carter, Glenn M Marshall

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
7.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. LncRNA OTUD6B-AS1 overexpression promoted GPX4-mediated ferroptosis to suppress radioresistance in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  14. Article
  15. Review
  16. AshwagandhaPharmaceutics · 2023
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zsuzsanna NagyChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia.
Belamy B CheungChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia. bcheung@ccia.unsw.edu.au.
Wing TsangChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia.
Owen TanChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia.
Mika HerathChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia.
Olivia C CiampaChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia.
Fatima ShadmaChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia.
Daniel R CarterChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia.
Glenn M MarshallChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, PO Box 81, Randwick, NSW, 2031, Australia. g.marshall@unsw.edu.au.
UNSW Sydney · AUChildren's Cancer Institute Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although selective BRAF inhibitors and novel immunotherapies have improved short-term treatment responses in metastatic melanoma patients, acquired resistance to these therapeutics still represent a major challenge in clinical practice. In this study, we evaluated the efficacy of Withaferin A (WFA), derived from the medicinal plant Withania Somnifera, as a novel therapeutic agent for the treatment of melanoma. WFA showed selective toxicity to melanoma cells compared to non-malignant cells. WFA induced apoptosis, significantly reduced cell proliferation and inhibited migration of melanoma cells. We identified that repression of the tumour suppressor TRIM16 diminished WFA cytotoxicity, suggesting that TRIM16 was in part responsible for the cytotoxic effects of WFA in melanoma cells. Together our data indicates that WFA has potent cytopathic effects on melanoma cells through TRIM16, suggesting a potential therapeutic application of WFA in the disease.

Indexed as

Antineoplastic AgentsApoptosisCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMelanomaTripartite Motif ProteinsTumor Cells, CulturedUbiquitin-Protein LigasesWithanolidesAntineoplastic AgentsTRIM16 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligaseswithaferin AWithanolides

Identifiers

PMID33184347
PMCPMC7665169
OpenAlexW3105597995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.